Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 10h12 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides...
PSMA Targeted Therapy Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 10h01 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "PSMA - Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic information on...
Bispecific Antibody Drug Conjugates Market Opportunity Outlook 2024-2029: China Leads Over 35 Candidates, Key Companies Pioneering BsADC are Amgen, Innovent Biologics, AstraZeneca
14 oct. 2024 05h52 HE
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to...
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10 oct. 2024 21h00 HE
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
03 sept. 2024 21h00 HE
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...
Global Biologics Contract Development and Manufacturing Organizations Market Report 2024-2029: End-to-end mRNA Services & Expanding Drug Capabilities to Support Anti-obesity Drugs Fuels Opportunities
31 juil. 2024 09h41 HE
|
Research and Markets
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024-2029" report has been added to ResearchAndMarkets.com's...
Vulvar Cancer Pipeline Insight 2024, with Key Focus on TAK-242, Vudalimab, PEN-866, Artesunate, IRX-2, ISA101, VicOryx, PRV111, PRGN-2009, ABI-2280 and CUE-101
16 avr. 2024 12h46 HE
|
Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Vulvar Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive...
Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: 800+ Bispecific Candidates Currently in Active Clinical Development
18 mars 2024 05h16 HE
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...
$7.25 Bn Antibody Fragments Markets - Global Industry Size, Share, Trends, Opportunity, and Forecasts to 2028
15 janv. 2024 08h58 HE
|
Research and Markets
Dublin, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The "Antibody Fragments Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...
Bispecific Antibody Competitive Landscape Report Unveils Comprehensive Insights on Therapeutics Assessment and Growth Dynamics in the Global Market
21 déc. 2023 09h48 HE
|
Research and Markets
Dublin, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The "Bispecific antibody - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. Amidst rapid advancements in the...